Tsutomu Nakazawa
Ryo Yamanishi3
Ryosuke Matusda- 1Grandsoul Research Institute for Immunology, Inc., Utano, Uda, Nara,, Japan
- 2Department of Neurosurgery, Nara Medical University, Shijocho, Kashihara, Nara, Japan
- 3Social Welfare Organization HIRAKATA RYOIKUEN, Hirakata, Osaka, Japan
- 4Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA, United States
One of the most significant risk factors for diseases is aging. Interestingly, some organisms, such as naked mole-rats and most turtles, do not exhibit typical aging-like symptoms or increased mortality as they become older. These aspects indicate that aging is not necessarily an essential event for animal life and are avoidable. Overcoming aging would free humans from age-associated diseases (AADs) and prolong lifespans. Recent studies have demonstrated that one of the causes of age-related organ dysfunction is excessive chronic inflammation caused by the accumulation of senescent cells (SNCs) and their senescence-associated secretory phenotypes (SASPs). Therefore, the development of drugs and medication to remove SNCs is ongoing. Natural killer (NK) cells are integral components of the innate immune system that are critical for clearing SNCs. Beyond this direct function, NK cells also orchestrate innate and adaptive immunity responses to survey and eradicate these compromised cells. Consequently, preserving NK cell function throughout the aging process is paramount for mitigating AADs and promoting robust health in later life. Simultaneously, NK cell-based senotherapy presents compelling avenues for addressing the multifaceted challenges associated with SNC accumulation and aging. Recent investigations into adoptive NK cell-based senotherapy have demonstrated considerable promise in rejuvenating immunosenescence, facilitating SNC elimination. The accumulating evidence provides a promising proof-of-concept for adoptive NK cell-based senotherapy, indicating its potential as a development in longevity therapeutics.
1 Introduction
The long-accepted idea of a 120-year maximum human lifespan gained its first statistical validation only in 2016 through innovative artificial data modeling (1). While average human lifespans have increased significantly, the question of maximum lifespan flexibility remains contentious. Research in model organisms has clearly demonstrated that lifespan is responsive to environmental and genetic manipulation (2–4), suggesting that humans might also possess a malleable maximal longevity. Yet, recent findings have controversially indicated that the ascent of the maximum human lifespan may have halted or reversed (1). This re-evaluation of human longevity coincided with a broader scientific challenge to the assumption that aging is a universal, inevitable biological process (5). Critically, species such as turtles (6, 7) and naked mole-rats (8, 9) exhibit “negligible senescence”, defying the typical age-related increase in mortality risk and physical signs of aging. These examples fundamentally bring into question the status of aging as a conserved life characteristic and propose that it could be an intervening, even reversible, pathophysiological state. This review focuses on the burgeoning potential of adoptive natural killer (NK) cell therapy as an innovative strategy to promote healthy aging and longevity.
2 Aging and age-associated diseases in humans
The human lifespan has been extended over the past century, but has also created the global challenge of escalating old-age diseases. Aging remains a fundamental, progressive, and irreversible pathophysiological process (10, 11). The idea that aging could be influenced gained early traction with Northrop’s 1925 discovery that light intensity affected Drosophila growth and lifespan (2), drawing significant research and public attention. This was reinforced by the fact that caloric restriction delayed age-related conditions and extended longevity in rodent models (3), underscoring the potential for interventions. A pivotal moment occurred in 1983 with the isolation of the first long-lived Caenorhabditis elegans strain (4), presenting new frontiers in aging research. Biologists have long contended that aging is critical, yet often overlooked, in the etiology of numerous chronic human disorders (12). Indeed, aging is a recognized risk factor for a wide spectrum of common diseases, including neurodegenerative conditions such as Alzheimer disease (AD) (13–15), Parkinson disease (14, 16), cardiovascular disease (17, 18), chronic obstructive pulmonary disease (19, 20), metabolic disorders such as diabetes (21, 22), and musculoskeletal issues such as osteoporosis (23–25) and osteoarthritis (26, 27). Aging is also a primary contributor to frailty, a geriatric syndrome marked by diminished physiological reserves and increased susceptibility to stressors, stemming from multifaceted biological decline (28, 29). The reality for many aging individuals, especially those aged >60 years, is the management of multiple coexisting health conditions, frequently necessitating complex multi-therapy regimens for effective long-term care (30). Consequently, a profound understanding of the aging process is paramount to uncover novel therapeutic targets and facilitate the future development of clinically applicable pharmacological interventions, addressing the burden of chronic age-related diseases.
3 Aging and cellular senescence
Cellular senescence refers to the progressive loss of cellular proliferative and differentiation potential, along with a decline in physiological function over time. Cellular senescence represents a distinct and stable form of cell cycle arrest that is fundamental in tumor suppression in mammals. Beyond its protective effects, senescence exerts major influences on tissue homeostasis and contributes to a range of pathological conditions, rendering it a central driver of organismal aging and aging-associated diseases (11, 31, 32). Although cellular senescence is now recognized as a cornerstone concept in both cancer biology and geroscience, its importance was initially underappreciated. In 1956, cellular senescence was reported as the inability of repeatedly dividing cells to proliferate further when somatic cells derived from normal mammalian tissues were cultured in vitro (33). A few years later, in 1961, Hayflick described the finite proliferative capacity of cultured human fibroblasts, an idea that initially faced skepticism from the scientific community (34). However, accumulating evidence over subsequent decades has firmly established senescence as a pivotal physiological and pathological process. Serrano et al. reported on oncogenic-induced senescence (OIS), in which the expression of mutant Ras also induces a state of growth arrest similar to replicative senescence (35). In 2005, cellular senescence was reported to function as an important cancer suppression mechanism in precancerous lesions and benign tumors in vivo (36–39). Contemporary research continues to contend with challenges, specifically the definition and heterogeneity of senescent cells (SNCs) in vivo (40), but the concept is now indispensable, even among its early critics. A growing body of work has elucidated numerous molecular mechanisms underlying senescence regulation, including telomere attrition (41), mitochondrial dysfunction (42), epigenetic alterations (43) impaired proteostasis (44), and stem cell exhaustion (45). Collectively, these features constitute the key hallmarks of aging. Importantly, many of these processes are orchestrated by persistent oxidative stress and elevated reactive oxygen species (ROS) levels, which both trigger and amplify senescence-associated pathways (46).
In normal cells, SNCs are characterized by a stable, stress-induced cessation of the cell cycle in cells that were once proliferative. First documented in cultured human fibroblasts with finite replicative capacity (34, 47), SNCs have since been observed in vivo, where their prevalence increases with age across mammalian species, including humans (48–51). These cells exhibit hallmark features such as irreversible growth arrest, upregulation of cell cycle inhibitors such as p16INK4a, and activation of stress-responsive signaling pathways including p38 MAPK and NF-κB, that collectively drive the transcriptional reprogramming characteristic of the senescent phenotype (40, 52, 53). This cell cycle arrest is most frequently triggered by a persistent DNA damage response (DDR) or sustained stress signaling, typically mediated through constitutive activation of the p16INK4a– retinoblastoma protein (RB) and/or p53 pathways (54). Although SNCs lose their proliferative potential, they remain metabolically active (55) and may preserve certain functional properties of their progenitors. A key driver of the senescence program is activation of the CDKN2A locus, which encodes both p16INK4a and alternate reading frame (ARF). Normally repressed in healthy tissues, CDKN2A is robustly induced by genotoxic or age-associated stress. Notably, p16INK4a expression increases sharply with age and has become one of the most widely used biomarkers for identifying SNCs in vivo (49, 56–60).
Another well-recognized hallmark of SNCs is elevated lysosomal β-galactosidase activity, detectable under near-neutral conditions as senescence-associated β-galactosidase (SA-β-gal) staining. This marker was first described in 1995 by Dimri et al., who observed that only senescent, but not proliferating, cells developed a distinctive signal when β-galactosidase activity was assayed at pH 6.0 (48). They introduced a cytochemical assay in which cleavage of the chromogenic substrate X-Gal produces a blue precipitate, enabling the visualization of SNCs. Since then, more refined quantitative methods have been developed to assess SA-β-gal activity at pH 6.0 (61–63). Importantly, this activity reflects the increased expression and accumulation of endogenous lysosomal β-galactosidase in SNCs. However, the enzyme is not required for inducing or maintaining senescence (63). In addition to SA-β-gal activity, SNCs are characterized by the secretion of a diverse array of proinflammatory cytokines, chemokines, growth factors, and proteases, collectively termed senescence-associated secretory phenotypes (SASPs) (64). Although the precise SASP composition varies by cell type and context, its production is largely governed by NF-κB and p38 MAPK signaling and tightly regulated by mammalian target of rapamycin (mTOR)-dependent translational control (65–69). Notably, the SASP has been recognized as a key driver of age-associated tissue dysfunction, highlighting the pathological effects of SNCs on both aging and chronic disease (64, 66). Beyond these features, additional senescence-associated characteristics have been reported, including critically short telomeres, DNA segments with chromatin alterations reinforcing senescence (DNA-SCARS), persistent DDR, NF-κB signaling activation, and the formation of senescence-associated heterochromatin foci (SAHFs).
Cellular senescence is beneficial in tissue remodeling, wound healing, and tumor suppression. However, as individuals age, the accumulation of SNCs coupled with persistent SASP secretion contributes to chronic inflammation, impairs tissue function (31, 70, 71), and fuels development of AADs. The first demonstrations that eliminating SNCs in vivo could extend lifespan and improve health were from genetic models (INK-ATTAC transgenic mice) (57). The studies ablated p16Ink4a-SNCs using inducible “suicide genes”, and not drugs. The selective clearance of SNCs, known as senolytics, was first successfully tested as pharmacological senotherapy ABT263 (Navitoclax) in a preclinical in vivo model, leading to the development of several current senolytic agents (72).
4 Immunosenescence
Immunosenescence refers to the gradual deterioration of the immune system that occurs with advancing age, affecting both innate and adaptive immunity. This phenomenon contributes to increased susceptibility to infections, cancer, and reduced vaccine efficacy, while also fostering chronic low-grade inflammation (“inflammaging”), which underlies many AADs (73–75). Yousefzadeh et al. provided a comprehensive and broad overview of the effects of senescent immune cells on cells distributed throughout various organs. They established a conditional knockout mouse by deleting the excision repair cross-complementation group 1 (Ercc1) gene, which is needed for DNA repair, only in blood and immune cells. The mice appeared normal when young, but their immune cells aged quickly, exhibiting loss of function and signs of senescence. The aged immune cells then released harmful signals that spread aging to other organs such as the liver, kidney, lung, brain, and muscles, causing tissue damage and decline. Furthermore, transplanting old or Ercc1-deficient immune cells into young mice resulted in premature aging in the young mice. Contrastingly, transplanting young immune cells into diseased mice reduced aging signs. Rapamycin treatment improved immune cell function and decreased senescence. The study demonstrated that immune-specific DNA repair defects accelerate immunosenescence, and that senescent immune cells actively drive whole-body aging. Targeting these cells may aid in delaying age-related decline and extend healthy lifespans (76).
Numerous reports have been published on senescence immunity for each cell type. In the adaptive immune system, aging is characterized by thymic involution and a consequent decline in naïve T cell output, leading to restricted T cell receptor (TCR) diversity (77, 78). Additionally, an accumulation of memory and senescent-like T cells, frequently driven by persistent antigenic stimulation such as cytomegalovirus (CMV) infection, further skews T cell repertoires and impairs immune responsiveness (79, 80). Furthermore, B cell compartments undergo profound changes, including decreased generation of naïve B cells, impaired somatic hypermutation, and reduced antibody diversity, which all compromise humoral immunity (81, 82).
In the innate immune system, immunosenescence manifests as reduced function of dendritic cells (DCs), neutrophils, and NK cells, coupled with impaired macrophage phagocytic activity (83–85). NK cells are of particular interest, as both their number and cytotoxic capacity may decline with age, limiting their ability to clear virus-infected cells, tumor cells, or SNCs (86, 87). With aging, macrophages display altered polarization, impaired phagocytosis, and dysregulated cytokine production. Aged macrophages exhibit reduced responsiveness to pattern-recognition receptor (PRR) signaling, including Toll-like receptors (TLRs), leading to impaired pathogen clearance (88, 89). Aged macrophages also exhibit defective efferocytosis (clearance of apoptotic cells), contributing to chronic inflammation and tissue dysfunction (90). Moreover, age-associated skewing toward a proinflammatory M1-like phenotype, along with impaired M2-mediated tissue repair, promotes inflammaging and impaired resolution of inflammation (91, 92). Similarly, DC function is compromised with age. Although total DC numbers may remain relatively stable, their ability to sense danger signals, migrate to lymphoid tissues, and prime naïve T cells declines significantly (93, 94). Aged DCs demonstrate impaired TLR signaling, diminished type I interferon (IFN) responses, and reduced antigen-presenting capacity (95, 96). This contributes to weakened adaptive immune responses, including diminished vaccine efficacy in older individuals (83). Moreover, DCs from elderly individuals tend to produce higher basal levels of proinflammatory cytokines, contributing to inflammaging while simultaneously failing to mount robust protective responses (97, 98). Together, macrophage and DC immunosenescence weaken host defense, impair tissue homeostasis, and exacerbate age-associated inflammation. Collectively, immunosenescence weakens protective immunity and drives a proinflammatory milieu, linking aging with the pathogenesis of cardiovascular disease, neurodegeneration, frailty, and cancer (99, 100).
5 NK cells and SNCs
NK cells are bone-marrow-derived innate immune lymphocytes that constitute approximately 10–20% of peripheral blood lymphocytes. NK cells are central to the ability of the immune system to identify and eliminate abnormal cells, including virus-infected cells, tumor cells, and SNCs. NK cells are classified into two subsets: CD56 dim (cytotoxic) and CD56 bright (cytokine-producing). NK cell function is governed by a balance between activating [e.g., NKG2D, DNAX accessory molecule-1 (DNAM-1)] and inhibitory receptors [e.g., killer-cell immunoglobulin-like receptor (KIRs)] (101). SNCs express stress-induced ligands such as major histocompatibility complex (MHC) class I chain-related protein A/B (MICA/B) and CD155, rendering them susceptible to NK cell-mediated cytotoxicity. In addition to direct killing via degranulation (perforin, granzyme B), NK cells orchestrate immune responses through cytokine secretion and crosstalk with T cells and macrophages (13, 102).
SNCs display a range of stress-induced surface ligands that render them susceptible to NK cell-mediated clearance. A major pathway involves the NKG2D receptor, which recognizes ligands upregulated during senescence, including MICA, MICB, and UL16-binding proteins (ULBP1–6) in humans, and retinoic acid early inducible 1 (RAE-1), murine UL16-binding protein-like transcript (MULT-1), and H60 in mice (103, 104). These ligands are frequently induced by persistent DDR, oncogenic stress, and ROS (105). SNCs can also be recognized through DNAM-1 and CD226 [T cell immunoreceptor with Ig and ITIM domains (TIGIT)] interactions with its ligands CD112 (Nectin-2) and CD155 [poliovirus receptor (PVR)], which are elevated on senescent fibroblasts and epithelial cells (106, 107). Santara et al. recently reported that NK cells recognize SNCs through the upregulation of stress-induced ligands, including NKp46 ligands. They identified ecto-calreticulin as the long-sought endogenous ligand for NKp46 and demonstrated that NK cells use this pathway to sense endoplasmic reticulum (ER)-stress and SNCs, linking stress responses to immune surveillance (108). NK cells can eliminate SNCs by NK activating receptor recognition via cytotoxic mechanisms, including perforin- and granzyme-mediated killing (103, 109). However, SNCs can develop immune evasion mechanism. Downregulating human leukocyte antigen (HLA) class I molecules in SNCs reduced inhibitory signaling by killer-cell immunoglobulin-like receptors (KIRs) and sensitized them to NK cell cytotoxicity (110). The overexpression of HLA-E, which engages the inhibitory receptor NKG2A on NK cells, has been reported as a strategy for SNCs to escape immune clearance (109). Collectively, these results demonstrate that NK cell surveil SNCs primarily via a balance between activating receptor pathways mediated by NKG2D, DNAM-1, and NKp46 and inhibitory receptor pathways mediated by KIRs and NKG2A (Figure 1). But their efficacy declines with age, leading to SNC accumulation and contributing to tissue dysfunction.
Figure 1. Recognition of NK cell on SNC. NK cells recognize SNCs through a balance of activating and inhibitory receptor signals. Activating receptors such as NKG2D, DNAM-1, and NKp46 engage their respective ligands—MIC/ULBP, nectin-2/PVR, and ecto-calreticulin—on SNCs. Inhibitory receptors, including NKG2A and killer cell immunoglobulin-like receptors (KIRs), interact with HLA-E and classical HLA class I molecules. The balance of these activating and inhibitory inputs determines NK cell responsiveness. Upon recognizing SNCs, NK cells release cytotoxic granules containing granzyme B and perforin, as well as immunostimulatory cytokines such as IFN-γ. Granzyme B and perforin directly induce apoptosis in SNCs, whereas IFN-γ promotes systemic immune activation and could contribute to the clearance of SNCs indirectly. NK, natural killer cell; SNC, Senescent cell.
6 Effects of NK cells on AADs
Historically, immunogerontology research primarily investigated the age-related decline of adaptive immunity (111). An increasing body of evidence now underscores the critical role of innate immunity in the pathogenesis of AADs (70, 102, 106). NK cells have a unique and indispensable position in the innate immune system and are specialized in recognizing and eliminating aberrant cells, such as tumor and virus-infected cells (112–118). Notably, NK cells have also been demonstrated to target SNCs (106, 119, 120) and contribute to immune surveillance by producing cytokines and chemokines, which facilitate the recruitment and activation of other immune cells within the tumor microenvironment (121, 122). Remarkably, research on healthy older adults (those who maintain physical fitness, independence in daily activities, and robust cognitive function) revealed that both the quantity and functional competence of their NK cells were well preserved (123–126). In stark contrast, compromised NK cell function in elderly individuals was associated with a heightened susceptibility to conditions such as atherosclerosis (127) and an elevated risk of all-cause mortality (61, 62). These results underscore that sustaining NK cell functionality is considered essential for promoting healthy aging and contributing to an extended lifespan (106, 128).
NK cells in aging undergo characteristic changes collectively termed immunosenescence. NK cell immunosenescence is manifested by reduced cytotoxicity, impaired cytokine production, and altered receptor expression (84, 87). NK cell subsets are redistributed with age: mature CD56dim cell increase and immunoregulatory CD56bright cells are reduced. Phenotypic alterations include the loss of activating receptors such as NKp30, NKp46, and DNAM-1, alongside an increase in CD57 and NKG2C, frequently influenced by chronic CMV infection (129). Functionally, elderly NK cells demonstrate reduced proliferation and per-cell cytotoxicity, despite preserved antibody-dependent cytotoxicity. Furthermore, cytokine secretion patterns shift, potentially fueling systemic inflammation (84, 130–133). Consequently, SNC clearance declines with age, leading to their accumulation and exacerbation of tissue dysfunction. This impaired NK–SNC axis has been linked to the progression of atherosclerosis, pulmonary fibrosis, sarcopenia, frailty, and cancer (134, 135).
NK cells in AD exhibit complex, and occasionally contradictory, changes. Experimental AD models (triple transgenic mice) exhibited NK alterations before disease onset, suggesting NK dysregulation as an early marker. In humans, the absolute numbers of NK cells in mild cognitive impairment (MCI) or AD are not consistently altered. NK cells also interact with astrocytes and microglia, the main innate immune cells of the brain. Cytokines and complement activation promote NK recruitment across a compromised blood–brain barrier in AD, fueling neuroinflammatory cascades. NK cells may play a dual role in AD: impaired surveillance against pathogens and tumors, but exaggerated inflammatory responses that aggravate neuronal injury. Profiling NK subsets, receptors, and migratory patterns could yield disease progression biomarkers, while therapies targeting NK dysfunction may aid in modulating neuroinflammation in AD (129, 136). These changes contribute to immune evasion by SNCs and subsequent AAD progression, including AD. Lifestyle factors such as exercise and nutrition influence NK cell health, suggesting modifiable pathways to maintain immune surveillance in aging populations (70, 71).
7 Evidence for NK cell-based senotherapy
In the above context, NK cell-based immunotherapies, especially adoptive NK cell therapy, are drawing considerable attention (Figure 2). These therapies have been clinically validated for treating cancers and viral infections (137, 138), and hold promise for reversing immunosenescence, eliminating SNCs, and attenuating the SASP that contributes to AAD pathogenesis (139–141). Among the immune cells, NK cells have garnered significant interest due to their innate capacity to recognize and remove SNCs (70, 71, 102).
Figure 2. The schematic representation of the potential of adoptive NK cell-based senotherapy for healthy longevity. Cells proliferate through continuous progression of the cell cycle. Upon genomic damage or cellular stress, cell-cycle checkpoint mechanisms are activated, leading to apoptosis or senescence. The induction of senescence is regulated in part by the cyclin-dependent kinase inhibitors p16 and p21. These checkpoint pathways function as critical biological defense systems to suppress malignant transformation. However, with aging, SNCs accumulate in tissues. SNCs secrete SASPs and promote chronic inflammation. Persistent chronic inflammation contributes to the development of multiple disorders including cancers collectively referred to as AAD. Activated and expanded NK cells possess the ability to recognize and directly eliminate SNCs, thereby exerting senolytic activity. NK, natural killer cell; SNC, Senescent cell; SASP, senescence-associated secretory phenotypes; AAD, aging-associated diseases.
The following accumulating results provide a mechanistic basis for NK cell-based senotherapy. Preclinical studies have demonstrated that NK cells can effectively clear senescent fibroblasts, hepatic stellate cells, and pre-malignant cells in vivo, limiting fibrosis, tumorigenesis, and chronic inflammation (54, 142). In murine models of liver injury, NK cell depletion led to the accumulation of senescent stellate cells and exacerbated fibrosis, whereas NK cell activity promoted tissue remodeling and recovery (142). Similarly, NK cells delayed tumor initiation by eliminating senescent premalignant cells that otherwise fuel tumorigenesis through SASP-driven inflammation (54, 142). These results highlight NK cell surveillance as an intrinsic senotherapeutic mechanism.
Adoptive NK cell transfer is a therapeutic strategy in which NK cells are isolated, expanded, and occasionally genetically or pharmacologically modified ex vivo, then reinfused into patients to restore or enhance NK cell function. The exploration of various sources for therapeutic NK cells, potentially customizable to target cancer and SNCs, is ongoing (138, 143–145). Recent pilot studies have reported that the adoptive transfer of autologous ex vivo-expanded NK cells reduced SNCs in peripheral blood mononuclear cells (PBMCs) of elderly individuals. In 26 volunteers, autologous NK cell infusion reduced senescence markers (p16, p21) and SA-β-gal in peripheral CD3+ T cells (141). Chelyapov et al. conducted an in vitro study using PBMCs from five healthy volunteers, where ex vivo-expanded autologous NK cells were co-cultured with PBMCs. Significant reductions in cells positive for the senescence markers p16 and SA-β-gal were observed post-treatment, with increased expression of activation markers such as CD69 and perforin. The effect lasted several months, but gradually returned to baseline. Repeated infusions prolonged the reduction in senescence markers. Inflammatory proteins such as IL-6, IFN-γ, and MCP-1 decreased post-infusion, while regulated on activation, normal T-cell expressed and secreted (RANTES) increased. No adverse effects or abnormal blood test results were observed (140). A prospective, open-label, randomized controlled trial by Tang et al. enrolled 25 elderly participants who were randomly assigned to receive either autologous NK cell transfusions or no treatment. Over a 90-day follow-up period, the treatment group exhibited a statistically significant decrease in senescent T cell subsets and circulating proinflammatory cytokines, alongside improvements in immune profiling markers. Furthermore, the NK cell transfusion group had decreased exhausted T cells (139). Although these studies are limited in scale and require further validation through larger randomized controlled trials, the results suggest that adoptive NK cell therapy is safe, well-tolerated, and potentially effective in alleviating systemic immunosenescence and reducing the SNC burden in humans.
8 Current senotherapy and the advantage of NK cell-based senotherapy
Senotherapeutic strategies are divided into two major categories: senolytics, which selectively induce apoptosis in SNCs, and senomorphics (or SASP modulators), which suppress the harmful proinflammatory phenotype without removing the cells. Numerous preclinical studies have demonstrated that targeting SNCs ameliorates tissue dysfunction, reduces inflammation, and improves health span across various disease models (Table 1). Importantly, accumulating evidence now suggests that senolytic and senomorphic strategies are not mutually exclusive, but rather may function in a complementary manner when rationally combined with immune-mediated senescence clearance.
Table 1. Current therapeutic strategies targeting cellular senescence.
One of the earliest senolytic combinations combined the tyrosine kinase inhibitor dasatinib with quercetin, a flavonoid with pleiotropic actions. This combination was efficacious in models of idiopathic pulmonary fibrosis, atherosclerosis, and aging-related physical dysfunction (146). Intermittent administration of dasatinib/quercetin reduced SNC burden and ameliorated tissue pathology in multiple organs (146, 147). Fisetin is a natural flavonol with senolytic activity across several SNC types. Fisetin reduced the expression of p16Ink4a and SASP factors in aged mice, improved renal function, and extended lifespan in certain models (148). Furthermore, fisetin benefited muscle strength, mitochondrial function, and reduced tissue fibrosis (149). The BCL-2 and BCL-xL inhibitor Navitoclax induced apoptosis in SNCs by disrupting the SNC anti-apoptotic pathways (SCAPs). Preclinical studies demonstrated that navitoclax effectively cleared SNCs in the lung, liver, and hematopoietic systems, reducing fibrosis and enhancing regeneration (150). However, its clinical development is limited by thrombocytopenia due to BCL-xL inhibition in platelets (151). Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that can clear some SNC subsets (e.g., therapy-induced senescent lymphoid cells), but was less potent than Navitoclax (150, 152, 153). Many SNCs depend on BCL-2 family proteins (BCL-2, BCL-xL, BCL-w) for survival. Many SNC types rely more on BCL-xL than BCL-2. As Venetoclax selectively targets BCL-2, it is less potent than Navitoclax.
Cardiac glycosides such as digoxin have been identified as senolytic agents that target Na+/K+–ATPase and disrupt ion homeostasis preferentially in human SNCs (154). Digoxin reduced senescence marker expression in murine in vivo fibrosis models (e.g. lung fibrosis induced via senescent fibroblast instillation), ameliorated fibrotic histology, and suppressed SASP cytokines (155). Some studies on atherosclerosis models also reported decreases in vascular senescence burden and SASP with digoxin treatment (155), and multiple reviews have cited protective effects in preclinical models of pulmonary fibrosis, atherosclerosis, and type 2 diabetes (156). Originally developed for type 2 diabetes, sodium glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin are being repurposed as senomorphic/senolytic agents. Recent studies have demonstrated their ability to reduce senescence markers, improve endothelial and renal function, and suppress SASP components in both diabetic and non-diabetic models (157). Antibody-drug conjugate (ADC) targeting of SNC surface markers such as β-2 microglobulin (B2M) and urokinase plasminogen activator receptor (uPAR), which are upregulated in various SNC types, allows for selective clearance. Preclinical models have demonstrated a reduced SNC burden and alleviated tissue dysfunction without broad cytotoxicity (158).
Chimeric antigen receptor T cells (CAR-T cells) engineered to recognize uPAR or other senescence-specific markers have been efficacious in removing SNCs in models of liver and lung fibrosis. These approaches harness the immune system for targeted senescence clearance (159). As senomorphics and mixed mechanism agents, rapamycin suppresses mechanistic/mTOR complex 1 (mTORC1) signaling, a key regulator of SASP. Rapamycin reduced systemic inflammation in aged mice and progeroid models, preserved organ function, and extended lifespan (160). Furthermore, rapamycin suppressed secondary senescence and promoted autophagy (161). Drugs such as ruxolitinib and momelotinib are used for myeloproliferative disorders, and inhibit SASP by blocking IL-6–STAT3 signaling. In senescent fibroblasts and irradiated tissues, these agents reduced proinflammatory cytokines and improved regeneration (162).
Metformin indirectly reduces SASP through AMPK activation and mitochondrial stabilization. It reduces p16 expression and systemic inflammation in diabetic and aging models, although its senolytic potency is limited (163). Lipophilic statins eliminate senescent endothelial cells by inducing anoikis−related cell death. In human endothelial cell (HUVEC) models of senescence, statins demonstrated senolytic activity (killing senescent endothelial cells while sparing non-SNCs) (164). Fularski et al. reported that statins reduce senescence features in endothelial progenitor cells and other vascular cell types (165). A retrospective human cohort study involved statin users versus non−users in adults with high atherosclerotic risk. Statin use was associated with slower progression of arterial stiffness (measured via brachial−ankle pulse wave velocity), especially in continuous users with high adherence over ~4.8 years (166). Their mechanism may involve inhibition of the mevalonate pathway.
Despite the promise of senotherapeutics, several challenges persist. Cellular heterogeneity among SNCs limits universal targeting. Furthermore, the lack of specific biomarkers complicates in vivo detection and treatment monitoring. Potential off-target effects may disrupt beneficial senescence functions (e.g., in wound healing). Translation from mice to humans is hindered by species-specific differences in drug metabolism and senescence phenotypes. Consequently, alternative methodologies capable of safely eliminating a broad spectrum of human SNCs should be investigated. Hence, alternative strategies such as immunological clearance are gaining interest (141). Furthermore, targeting immunosenescence and SNCs has emerged as a pivotal therapeutic strategy for promoting and maintaining healthy aging (111, 167, 168). Compared to senolytics, NK cell-based senotherapy offers greater specificity, reduced systemic toxicity, and the potential for long-lasting effects following a single administration (140). Unlike tumor environments, inflamed tissues with high SNC load support NK cell migration and activation. This localized targeting reduces the risk of off-target effects and enhances therapeutic efficacy.
Importantly, senomorphic agents that suppress SASP and modulate inflammatory tissue microenvironments may further enhance NK cell infiltration, persistence, and cytotoxic activity against residual SNCs. Thus, a combinatorial strategy integrating senomorphic modulation with NK cell-based immune clearance represents a highly rational and potentially synergistic approach for durable senotherapy.
9 Biomarkers for NK cell-based senotherapy
The identification of reliable biomarkers is central to the advancement of senotherapies, as they allow for the detection of SNC burden, monitoring of therapeutic response, and prediction of clinical outcomes. Senescence biomarkers are typically divided into molecular, cellular, and functional categories. The following accumulating results support the use of multi-parametric biomarker panels, rather than single readouts, to monitor senotherapy outcomes.
Molecular Biomarkers: The canonical markers include p16INK4a and p21CIP1, which are cyclin-dependent kinase inhibitors reflecting stable cell cycle arrest (40, 169). The accumulation of DNA damage foci, such as γH2AX and 53BP1, also indicates a persistent DDR (170). Additionally, the SASP, consisting of cytokines, chemokines, and proteases (e.g., IL-6, IL-8, Matrix Metalloproteinases (MMPs)), is a measurable systemic biomarker linked to age-related inflammation and tissue dysfunction (105). Emerging epigenetic signatures, including senescence-associated DNA methylation profiles, provide complementary information to classical epigenetic aging clocks (171).
Cellular Biomarkers: SNCs are commonly identified by SA-β-gal activity, reflecting enhanced lysosomal content (48). More recently, cell surface molecules have been recognized as actionable biomarkers, including uPAR (159), B2M, and DPP4/CD26, and immune receptor ligands such as MICA/B and ULBPs that engage NK cells (103). These markers allow both therapeutic targeting and immune surveillance. Functional readouts, such as NK cell-mediated clearance capacity against SNCs, are increasingly considered surrogate biomarkers of therapy efficacy (134). Both SNCs and NK cells undergo functional decline with aging or chronic stress. SNCs may downregulate activating ligands or secrete SASP factors that suppress NK cell function (109). In parallel, elderly individuals’ NK cells exhibit impaired cytotoxicity, reduced perforin/granzyme release, and altered receptor expression, diminishing their capacity to clear SNCs (86, 87). This reciprocal dysfunction promotes SNC accumulation and contributes to inflammaging. Functional assays measuring NK cell activity against SNCs are increasingly proposed as surrogate biomarkers of senotherapy efficacy. Measuring NK degranulation (CD107a expression), CD69, perforin/granzyme release, or IFN-γ production provides a readout of functional rejuvenation (141). Ovadya et al. emphasized that NK cell clearance capacity could be a biomarker in senotherapy trials (134). For example, the successful elimination of SNCs by senolytic drugs may be reflected in reduced SASP factors and in restored NK cell effector function. Therefore, NK-mediated clearance assays bridge the gap between molecular markers and systemic outcomes, including improved physical function.
Circulating Biomarkers: Circulating SASP factors, cell-free DNA, and extracellular vesicles reflect the systemic senescence burden (172). Inflammatory mediators such as C-reactive protein (CRP) and TNF-α correlate with age-related SNC accumulation (99).
10 Future directions of NK cell-based senotherapy
Adoptive NK cell transfer is an NK cell-based senotherapy. However, further research is needed to optimize NK cell culture conditions, define dosing schedules, and assess the effects of donor age. In particular, donor aging is a critical determinant of NK cell fitness, proliferative capacity, metabolic activity, and cytotoxic function, and may represent an inherent limitation of autologous NK cell-based approaches in elderly individuals. Although ex vivo activation and expansion can partially restore the effector functions of aged NK cells by NK cell stimulation (NK cell activation state), complete functional rejuvenation is not always guaranteed. In this context, the exploration of allogeneic NK cells, umbilical cord-derived NK cells, stem cell-derived NK cells, and CAR-NK cells may broaden clinical applicability. NK cell–based immunotherapies for cancer have been safely evaluated in numerous clinical trials (173). Allogeneic NK cell platforms offer several potential advantages, including superior cytotoxic potency, enhanced proliferative capacity, greater manufacturing consistency, and improved scalability, batch-to-batch manufacturing consistency, and improved scalability, which may be especially advantageous for senotherapy in aged populations where endogenous immune dysfunction is prevalent. From a regulatory perspective, the successful clinical implementation of NK cell-based senotherapy will require strict compliance with Good Manufacturing Practice (GMP) and, in Japan, the Act on the Safety of Regenerative Medicine and PMDA regulatory frameworks. Critical regulatory challenges include the establishment of fully standardized and validated manufacturing processes for NK cell isolation, activation, expansion, and cryopreservation under GMP-compliant conditions, along with rigorous in-process controls and release testing. These quality attributes must encompass cell identity, purity, viability, sterility, endotoxin levels, genomic stability, and functional cytotoxic potency. Moreover, robust and quantitative potency assays predictive of in vivo therapeutic efficacy will be mandatory to satisfy regulatory requirements, particularly for allogeneic and gene-modified NK cell products. Process validation, comparability studies following manufacturing changes, and long-term stability testing will also be essential components of regulatory submissions to ensure consistent product quality. With respect to safety evaluation, regulatory authorities will require comprehensive non-clinical and clinical data addressing long-term biodistribution, persistence, off-target cytotoxicity, immunogenicity, and the risk of unintended immune activation. These parameters are of particular importance in the context of repeated dosing regimens and administration to frail elderly individuals with compromised immune homeostasis. In addition, the potential risks associated with tumorigenicity, chromosomal instability, and gene-editing–related off-target effects in CAR-NK or stem cell–derived NK platforms must be rigorously assessed. Finally, large-scale randomized controlled trials will be indispensable to establish the clinical efficacy of NK cell-based senotherapy in extending health span and delaying the onset of AADs. The integration of regulatory science, GMP-compliant manufacturing, and well-designed clinical trials will be decisive for the broad clinical adoption, PMDA approval, and eventual commercialization of NK cell-based senotherapeutic interventions. Addressing these challenges will be crucial to facilitate broad clinical adoption and the development of commercially viable NK cell-based aging interventions.
In addition to adoptive NK cell transfer, therapeutic activation of endogenous NK cells represents an NK cell–based senotherapy. Endogenous NK cells play a central role in the immune surveillance of SNCs through activating receptors such as NKG2D, DNAM-1, and NKp46, which recognize stress-induced ligands upregulated on SNCs. However, aging and chronic inflammation impair NK cytotoxicity and cytokine responsiveness, contributing to immunosenescence. Recent studies have demonstrated that cytokine-mediated stimulation of NK cells, using interleukin (IL)-2, IL-12, IL-15, IL-18, or their combinations, can restore cytotoxicity, enhance IFN-γ production, and generate memory-like NK cell populations with superior effector function (174). This strategy can also be applied for ex vivo activation; however, direct administration of cytokines in vivo is likewise conceivable. Nevertheless, systemic cytokine injection carries a potential risk of adverse events, necessitating carefully designed clinical studies to confirm safety. More recently, clinical-grade IL-15 superagonists such as N-803 have been shown to induce robust in vivo expansion and activation of endogenous NK cells, illustrating the translational feasibility of this approach (175, 176). Additional strategies to enhance endogenous NK function include checkpoint blockade such as anti-NKG2A antibodies, which release NK cells from inhibitory signaling (177). These findings suggest that pharmacologic enhancement of endogenous NK activity may synergize with senolytic and senomorphic agents to promote more efficient clearance of SNCs. Taken together, these observations indicate that endogenous NK cell activation should be considered a core component of NK cell-based senotherapy, complementing both adoptive NK cell transfer and engineered NK cell approaches. By leveraging the natural distribution and tissue-resident potential of endogenous NK cells, this strategy may facilitate systemic and localized SNC clearance and enhance the durability of senotherapeutic interventions.
Although NK cell-based senotherapy are limited in scale and require further validation through larger randomized controlled trials, the results suggest that NK cell-based senotherapy is safe, well-tolerated, and potentially effective in alleviating systemic immunosenescence and reducing the SNC burden in humans.
11 Conclusion
NK cell-based senotherapy represents a promising frontier in preventative medicine targeting the root causes of aging. By leveraging the innate ability of NK cells to eliminate SNCs, this approach has potential to mitigate chronic inflammation, rejuvenate immune function, and improve age-related health outcomes. While clinical translation is in its infancy, the accumulating evidence paves the way for transformative strategies in aging and regenerative medicine.
Author contributions
TN: Writing – original draft, Writing – review & editing. RY: Writing – review & editing. TM: Writing – review & editing. RM: Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
TN was employed by company Grandsoul Research Institute for Immunology, Inc.
The remaining authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Dong X, Milholland B, and Vijg J. Evidence for a limit to human lifespan. Nature. (2016) 538:257–9. doi: 10.1038/nature19793
2. Northrop JH. The influence of the intensity of light on the rate of growth and duration of life of drosophila. J Gen Physiol. (1925) 9:81–6. doi: 10.1085/jgp.9.1.81
3. McCay CM, Maynard LA, Sperling G, and Barnes LL. Retarded growth, life span, ultimate body size and age changes in the albino rat after feeding diets restricted in calories. Nutr Rev. (1975) 33:241–3. doi: 10.1111/j.1753-4887.1975.tb05227.x
4. Klass MR. A method for the isolation of longevity mutants in the nematode Caenorhabditis elegans and initial results. Mech Ageing Dev. (1983) 22:279–86. doi: 10.1016/0047-6374(83)90082-9
5. Jones OR, Scheuerlein A, Salguero-Gomez R, Camarda CG, Schaible R, Casper BB, et al. Diversity of ageing across the tree of life. Nature. (2014) 505:169–73. doi: 10.1038/nature12789
6. Reinke BA, Cayuela H, Janzen FJ, Lemaitre JF, Gaillard JM, Lawing AM, et al. Diverse aging rates in ectothermic tetrapods provide insights for the evolution of aging and longevity. Science. (2022) 376:1459–66. doi: 10.1126/science.abm0151
7. da Silva R, Conde DA, Baudisch A, and Colchero F. Slow and negligible senescence among testudines challenges evolutionary theories of senescence. Science. (2022) 376:1466–70. doi: 10.1126/science.abl7811
8. Buffenstein R. Negligible senescence in the longest living rodent, the naked mole-rat: insights from a successfully aging species. J Comp Physiol B. (2008) 178:439–45. doi: 10.1007/s00360-007-0237-5
9. Kawamura Y, Oka K, Semba T, Takamori M, Sugiura Y, Yamasaki R, et al. Cellular senescence induction leads to progressive cell death via the INK4a-RB pathway in naked mole-rats. EMBO J. (2023) 42:e111133. doi: 10.15252/embj.2022111133
10. Partridge L, Deelen J, and Slagboom PE. Facing up to the global challenges of ageing. Nature. (2018) 561:45–56. doi: 10.1038/s41586-018-0457-8
11. Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. (2022) 7:391. doi: 10.1038/s41392-022-01251-0
12. Niccoli T and Partridge L. Ageing as a risk factor for disease. Curr Biol. (2012) 22:R741–52. doi: 10.1016/j.cub.2012.07.024
13. Sagiv A and Krizhanovsky V. Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology. (2013) 14:617–28. doi: 10.1007/s10522-013-9473-0
14. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. (2019) 15:565–81. doi: 10.1038/s41582-019-0244-7
15. Cortes-Canteli M and Iadecola C. Alzheimer’s disease and vascular aging: JACC focus seminar. J Am Coll Cardiol. (2020) 75:942–51. doi: 10.1016/j.jacc.2019.10.062
16. Hoehn MM and Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. (1967) 17:427–42. doi: 10.1212/wnl.17.5.427
17. Kaufman P and Poliakoff H. Studies on the aging heart; the pattern of rheumatic heart disease in old age (a clinical pathological study). Ann Intern Med. (1950) 32:889–904. doi: 10.7326/0003-4819-32-5-889
18. Yan M, Sun S, Xu K, Huang X, Dou L, Pang J, et al. Cardiac aging: from basic research to therapeutics. Oxid Med Cell Longev. (2021) 2021:9570325. doi: 10.1155/2021/9570325
19. Hernandez Cordero AI, Yang CX, Yang J, Horvath S, Shaipanich T, MacIsaac J, et al. Airway aging and methylation disruptions in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med. (2022) 206:150–60. doi: 10.1164/rccm.202106-1440OC
20. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. (2022) 10:447–58. doi: 10.1016/S2213-2600(21)00511-7
21. Wilkerson HL. Problems of an aging population: public health aspects of diabetes. Am J Public Health Nations Health. (1947) 37:177–88. doi: 10.2105/AJPH.37.2.177
22. Bellary S, Kyrou I, Brown JE, and Bailey CJ. Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol. (2021) 17:534–48. doi: 10.1038/s41574-021-00512-2
23. Rubin CD. Age-related osteoporosis. Am J Med Sci. (1991) 301:281–98. doi: 10.1097/00000441-199104000-00012
24. Johnston CB and Dagar M. Osteoporosis in older adults. Med Clin North Am. (2020) 104:873–84. doi: 10.1016/j.mcna.2020.06.004
25. Grunewald M, Kumar S, Sharife H, Volinsky E, Gileles-Hillel A, Licht T, et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science. (2021) 373:eabc8479. doi: 10.1126/science.abc8479
26. Rahmati M, Nalesso G, Mobasheri A, and Mozafari M. Aging and osteoarthritis: Central role of the extracellular matrix. Ageing Res Rev. (2017) 40:20–30. doi: 10.1016/j.arr.2017.07.004
27. Chen X, Gong W, Shao X, Shi T, Zhang L, Dong J, et al. METTL3-mediated m(6)A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression. Ann Rheum Dis. (2022) 81:87–99. doi: 10.1136/annrheumdis-2021-221091
28. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. (2013) 14:392–7. doi: 10.1016/j.jamda.2013.03.022
29. Kim DH and Rockwood K. Frailty in older adults. N Engl J Med. (2024) 391:538–48. doi: 10.1056/NEJMra2301292
30. Ding J, Lohman K, Molina A, Delbono O, Bertoni A, Shea S, et al. The association between aging-related monocyte transcriptional networks and comorbidity burden: the Multi-Ethnic Study of Atherosclerosis (MESA). Geroscience. (2023) 45:197–207. doi: 10.1007/s11357-022-00608-1
31. He S and Sharpless NE. Senescence in health and disease. Cell. (2017) 169:1000–11. doi: 10.1016/j.cell.2017.05.015
32. Di Micco R, Krizhanovsky V, Baker D, and d’Adda di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. (2021) 22:75–95. doi: 10.1038/s41580-020-00314-w
33. Haff RF and Swim HE. Serial propagation of 3 strains of rabbit fibroblasts; their susceptibility to infection with vaccinia virus. Proc Soc Exp Biol Med. (1956) 93:200–4. doi: 10.3181/00379727-93-22707
34. Hayflick L and Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. (1961) 25:585–621. doi: 10.1016/0014-4827(61)90192-6
35. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, and DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. (1996) 85:27–37. doi: 10.1016/s0092-8674(00)81079-x
36. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: senescence in premalignant tumours. Nature. (2005) 436:642. doi: 10.1038/436642a
37. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. (2005) 436:660–5. doi: 10.1038/nature03841
38. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. (2005) 436:720–4. doi: 10.1038/nature03890
39. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. (2005) 436:725–30. doi: 10.1038/nature03918
40. Sharpless NE and Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. (2015) 15:397–408. doi: 10.1038/nrc3960
41. Li Z, Zhou D, Zhang D, Zhao J, Li W, Sun Y, et al. Folic acid inhibits aging-induced telomere attrition and apoptosis in astrocytes in vivo and in vitro. Cereb Cortex. (2022) 32:286–97. doi: 10.1093/cercor/bhab208
42. Tracy TE, Madero-Perez J, Swaney DL, Chang TS, Moritz M, Konrad C, et al. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell. (2022) 185:712–28.e14. doi: 10.1016/j.cell.2021.12.041
43. van der Laan L, Cardenas A, Vermeulen R, Fadadu RP, Hubbard AE, Phillips RV, et al. Epigenetic aging biomarkers and occupational exposure to benzene, trichloroethylene and formaldehyde. Environ Int. (2022) 158:106871. doi: 10.1016/j.envint.2021.106871
44. Bharath LP, Agrawal M, McCambridge G, Nicholas DA, Hasturk H, Liu J, et al. Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. Cell Metab. (2020) 32:44–55.e6. doi: 10.1016/j.cmet.2020.04.015
45. Lei J, Jiang X, Li W, Ren J, Wang D, Ji Z, et al. Exosomes from antler stem cells alleviate mesenchymal stem cell senescence and osteoarthritis. Protein Cell. (2022) 13:220–6. doi: 10.1007/s13238-021-00860-9
46. Mossad O, Batut B, Yilmaz B, Dokalis N, Mezo C, Nent E, et al. Gut microbiota drives age-related oxidative stress and mitochondrial damage in microglia via the metabolite N(6)-carboxymethyllysine. Nat Neurosci. (2022) 25:295–305. doi: 10.1038/s41593-022-01027-3
47. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. (1965) 37:614–36. doi: 10.1016/0014-4827(65)90211-9
48. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U.S.A. (1995) 92:9363–7. doi: 10.1073/pnas.92.20.9363
49. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. (2006) 443:453–7. doi: 10.1038/nature05092
50. Melk A, Schmidt BM, Takeuchi O, Sawitzki B, Rayner DC, and Halloran PF. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int. (2004) 65:510–20. doi: 10.1111/j.1523-1755.2004.00438.x
51. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, et al. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell. (2009) 8:439–48. doi: 10.1111/j.1474-9726.2009.00489.x
52. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. (2013) 75:685–705. doi: 10.1146/annurev-physiol-030212-183653
53. Childs BG, Baker DJ, Kirkland JL, Campisi J, and van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. (2014) 15:1139–53. doi: 10.15252/embr.201439245
54. Munoz-Espin D and Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. (2014) 15:482–96. doi: 10.1038/nrm3823
55. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. (2013) 501:421–5. doi: 10.1038/nature12437
56. Zindy F, Quelle DE, Roussel MF, and Sherr CJ. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. (1997) 15:203–11. doi: 10.1038/sj.onc.1201178
57. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. (2011) 479:232–6. doi: 10.1038/nature10600
58. Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, et al. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell. (2013) 152:340–51. doi: 10.1016/j.cell.2012.12.010
59. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. (2014) 31:722–33. doi: 10.1016/j.devcel.2014.11.012
60. Yamakoshi K, Takahashi A, Hirota F, Nakayama R, Ishimaru N, Kubo Y, et al. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J Cell Biol. (2009) 186:393–407. doi: 10.1083/jcb.200904105
61. Bassaneze V, Miyakawa AA, and Krieger JE. A quantitative chemiluminescent method for studying replicative and stress-induced premature senescence in cell cultures. Anal Biochem. (2008) 372:198–203. doi: 10.1016/j.ab.2007.08.016
62. Itahana K, Campisi J, and Dimri GP. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol. (2007) 371:21–31. doi: 10.1007/978-1-59745-361-5_3
63. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. (2006) 5:187–95. doi: 10.1111/j.1474-9726.2006.00199.x
64. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PloS Biol. (2008) 6:2853–68. doi: 10.1371/journal.pbio.0060301
65. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. (2011) 25:2125–36. doi: 10.1101/gad.17276711
66. Freund A, Patil CK, and Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. (2011) 30:1536–48. doi: 10.1038/emboj.2011.69
67. Herranz N, Gallage S, Mellone M, Wuestefeld T, Klotz S, Hanley CJ, et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat Cell Biol. (2015) 17:1205–17. doi: 10.1038/ncb3225
68. Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. (2015) 17:1049–61. doi: 10.1038/ncb3195
69. Kang C, Xu Q, Martin TD, Li MZ, Demaria M, Aron L, et al. DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science. (2015) 349:aaa5612. doi: 10.1126/science.aaa5612
70. Fulop T, McElhaney J, Pawelec G, Cohen AA, Morais JA, Dupuis G, et al. Frailty, inflammation and immunosenescence. Interdiscip Top Gerontol Geriatr. (2015) 41:26–40. doi: 10.1159/000381134
71. Collerton J, Martin-Ruiz C, Davies K, Hilkens CM, Isaacs J, Kolenda C, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev. (2012) 133:456–66. doi: 10.1016/j.mad.2012.05.005
72. van Deursen JM. Senolytic therapies for healthy longevity. Science. (2019) 364:636–7. doi: 10.1126/science.aaw1299
73. Fulop T, Larbi A, and Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. (2013) 4:271. doi: 10.3389/fimmu.2013.00271
74. Franceschi C, Garagnani P, Parini P, Giuliani C, and Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. (2018) 14:576–90. doi: 10.1038/s41574-018-0059-4
75. Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. (2018) 19:10–9. doi: 10.1038/s41590-017-0006-x
76. Yousefzadeh MJ, Flores RR, Zhu Y, Schmiechen ZC, Brooks RW, Trussoni CE, et al. An aged immune system drives senescence and ageing of solid organs. Nature. (2021) 594:100–5. doi: 10.1038/s41586-021-03547-7
77. Palmer DB. The effect of age on thymic function. Front Immunol. (2013) 4:316. doi: 10.3389/fimmu.2013.00316
78. Goronzy JJ and Weyand CM. Mechanisms underlying T cell ageing. Nat Rev Immunol. (2019) 19:573–83. doi: 10.1038/s41577-019-0180-1
79. Pawelec G, Derhovanessian E, Larbi A, Strindhall J, and Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol. (2009) 19:47–56. doi: 10.1002/rmv.598
80. Wertheimer AM, Bennett MS, Park B, Uhrlaub JL, Martinez C, Pulko V, et al. Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J Immunol. (2014) 192:2143–55. doi: 10.4049/jimmunol.1301721
81. Frasca D and Blomberg BB. Aging affects human B cell responses. J Clin Immunol. (2011) 31:430–5. doi: 10.1007/s10875-010-9501-7
82. Cancro MP. Age-associated B cells. Annu Rev Immunol. (2020) 38:315–40. doi: 10.1146/annurev-immunol-092419-031130
83. Shaw AC, Goldstein DR, and Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. (2013) 13:875–87. doi: 10.1038/nri3547
84. Hazeldine J and Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev. (2013) 12:1069–78. doi: 10.1016/j.arr.2013.04.003
85. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, and Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol. (2012) 24:331–41. doi: 10.1016/j.smim.2012.04.008
86. Chidrawar SM, Khan N, Chan YL, Nayak L, and Moss PA. Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing. (2006) 3:10. doi: 10.1186/1742-4933-3-10
87. Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira J, Ribeiro Ados S, Falcao RR, et al. Age-related changes in natural killer cell receptors from childhood through old age. Hum Immunol. (2011) 72:319–29. doi: 10.1016/j.humimm.2011.01.009
88. Mahbub S, Deburghgraeve CR, and Kovacs EJ. Advanced age impairs macrophage polarization. J Interferon Cytokine Res. (2012) 32:18–26. doi: 10.1089/jir.2011.0058
89. Wong CK, Smith CA, Sakamoto K, Kaminski N, Koff JL, and Goldstein DR. Aging impairs alveolar macrophage phagocytosis and increases influenza-induced mortality in mice. J Immunol. (2017) 199:1060–8. doi: 10.4049/jimmunol.1700397
90. Aprahamian T, Takemura Y, Goukassian D, and Walsh K. Ageing is associated with diminished apoptotic cell clearance in vivo. Clin Exp Immunol. (2008) 152:448–55. doi: 10.1111/j.1365-2249.2008.03658.x
91. Linehan E and Fitzgerald DC. Ageing and the immune system: focus on macrophages. Eur J Microbiol Immunol (Bp). (2015) 5:14–24. doi: 10.1556/EUJMI-D-14-00035
92. Prattichizzo F, Bonafe M, Olivieri F, and Franceschi C. Senescence associated macrophages and “macroph-aging”: are they pieces of the same puzzle? Aging (Albany NY). (2016) 8:3159–60. doi: 10.18632/aging.101133
93. Agrawal A and Gupta S. Impact of aging on dendritic cell functions in humans. Ageing Res Rev. (2011) 10:336–45. doi: 10.1016/j.arr.2010.06.004
94. Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, and Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol. (2009) 70:777–84. doi: 10.1016/j.humimm.2009.07.005
95. Shaw AC, Joshi S, Greenwood H, Panda A, and Lord JM. Aging of the innate immune system. Curr Opin Immunol. (2010) 22:507–13. doi: 10.1016/j.coi.2010.05.003
96. Franceschi C, Bonafe M, and Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine. (2000) 18:1717–20. doi: 10.1016/s0264-410x(99)00513-7
97. Della Bella S, Bierti L, Presicce P, Arienti R, Valenti M, Saresella M, et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin Immunol. (2007) 122:220–8. doi: 10.1016/j.clim.2006.09.012
98. Agrawal A, Tay J, Yang GE, Agrawal S, and Gupta S. Age-associated epigenetic modifications in human DNA increase its immunogenicity. Aging (Albany NY). (2010) 2:93–100. doi: 10.18632/aging.100121
99. Franceschi C and Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. (2014) 69:S4–9. doi: 10.1093/gerona/glu057
100. Xia S, Zhang X, Zheng S, Khanabdali R, Kalionis B, Wu J, et al. An update on inflamm-aging: mechanisms, prevention, and treatment. J Immunol Res. (2016) 2016:8426874. doi: 10.1155/2016/8426874
101. Long EO, Kim HS, Liu D, Peterson ME, and Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. (2013) 31:227–58. doi: 10.1146/annurev-immunol-020711-075005
102. Kale A, Sharma A, Stolzing A, Desprez PY, and Campisi J. Role of immune cells in the removal of deleterious senescent cells. Immun Ageing. (2020) 17:16. doi: 10.1186/s12979-020-00187-9
103. Sagiv A, Burton DG, Moshayev Z, Vadai E, Wensveen F, Ben-Dor S, et al. NKG2D ligands mediate immunosurveillance of senescent cells. Aging (Albany NY). (2016) 8:328–44. doi: 10.18632/aging.100897
104. Raulet DH, Gasser S, Gowen BG, Deng W, and Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. (2013) 31:413–41. doi: 10.1146/annurev-immunol-032712-095951
105. Coppe JP, Desprez PY, Krtolica A, and Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. (2010) 5:99–118. doi: 10.1146/annurev-pathol-121808-102144
106. Antonangeli F, Zingoni A, Soriani A, and Santoni A. Senescent cells: Living or dying is a matter of NK cells. J Leukoc Biol. (2019) 105:1275–83. doi: 10.1002/JLB.MR0718-299R
107. Antonangeli F, Soriani A, Ricci B, Ponzetta A, Benigni G, Morrone S, et al. Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells. Oncoimmunology. (2016) 5:e1218105. doi: 10.1080/2162402X.2016.1218105
108. Sen Santara S, Lee DJ, Crespo A, Hu JJ, Walker C, Ma X, et al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature. (2023) 616:348–56. doi: 10.1038/s41586-023-05912-0
109. Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers ES, Subramanian P, Patel N, et al. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition. Nat Commun. (2019) 10:2387. doi: 10.1038/s41467-019-10335-5
110. Gergues M, Bari R, Koppisetti S, Gosiewska A, Kang L, and Hariri RJ. Senescence, NK cells, and cancer: navigating the crossroads of aging and disease. Front Immunol. (2025) 16:1565278. doi: 10.3389/fimmu.2025.1565278
111. Fulop T, Larbi A, Hirokawa K, Mocchegiani E, Lesourds B, Castle S, et al. Immunosupportive therapies in aging. Clin Interv Aging. (2007) 2:33–54. doi: 10.2147/ciia.2007.2.1.33
112. Tanaka Y, Nakazawa T, Nakamura M, Nishimura F, Matsuda R, Omoto K, et al. Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. PloS One. (2019) 14:e0212455. doi: 10.1371/journal.pone.0212455
113. Shida Y, Nakazawa T, Matsuda R, Morimoto T, Nishimura F, Nakamura M, et al. Ex vivo expanded and activated natural killer cells prolong the overall survival of mice with glioblastoma-like cell-derived tumors. Int J Mol Sci. (2021) 22:9975. doi: 10.3390/ijms22189975
114. Walzer T, Jaeger S, Chaix J, and Vivier E. Natural killer cells: from CD3(-)NKp46(+) to post-genomics meta-analyses. Curr Opin Immunol. (2007) 19:365–72. doi: 10.1016/j.coi.2007.04.004
115. Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, and Matsuda R. Natural killer cell-based immunotherapy against glioblastoma. Int J Mol Sci. (2023) 24:2111. doi: 10.3390/ijms24032111
116. Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma. J Exp Clin Cancer Res. (2023) 42:205. doi: 10.1186/s13046-023-02770-6
117. Lanier LL. Five decades of natural killer cell discovery. J Exp Med. (2024) 221:e20231222. doi: 10.1084/jem.20231222
118. Maeoka R, Matsuda R, Nakazawa T, Mochida Y, Ouji-Sageshima N, Yamada K, et al. Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of Malignant meningioma. BioMed Pharmacother. (2025) 187:118099. doi: 10.1016/j.biopha.2025.118099
119. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. (2008) 134:657–67. doi: 10.1016/j.cell.2008.06.049
120. Brighton PJ, Maruyama Y, Fishwick K, Vrljicak P, Tewary S, Fujihara R, et al. Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium. Elife. (2017) 6:e31274. doi: 10.7554/eLife.31274
121. Peterson EE and Barry KC. The natural killer-dendritic cell immune axis in anti-cancer immunity and immunotherapy. Front Immunol. (2020) 11:621254. doi: 10.3389/fimmu.2020.621254
122. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, and Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. (2006) 66:517–26. doi: 10.1158/0008-5472.CAN-05-2429
123. Cooper MA, Fehniger TA, and Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. (2001) 22:633–40. doi: 10.1016/s1471-4906(01)02060-9
124. Solana R and Mariani E. NK and NK/T cells in human senescence. Vaccine. (2000) 18:1613–20. doi: 10.1016/s0264-410x(99)00495-8
125. Ligthart GJ, Schuit HR, and Hijmans W. Natural killer cell function is not diminished in the healthy aged and is proportional to the number of NK cells in the peripheral blood. Immunology. (1989) 68:396–402.
126. Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood. (1993) 82:2767–73. doi: 10.1182/blood.V82.9.2767.2767
127. Bruunsgaard H, Pedersen AN, Schroll M, Skinhoj P, and Pedersen BK. Decreased natural killer cell activity is associated with atherosclerosis in elderly humans. Exp Gerontol. (2001) 37:127–36. doi: 10.1016/s0531-5565(01)00162-0
128. Camous X, Pera A, Solana R, and Larbi A. NK cells in healthy aging and age-associated diseases. J BioMed Biotechnol. (2012) 2012:195956. doi: 10.1155/2012/195956
129. Solana C, Tarazona R, and Solana R. Immunosenescence of natural killer cells, inflammation, and alzheimer’s disease. Int J Alzheimers Dis. (2018) 2018:3128758. doi: 10.1155/2018/3128758
130. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. (2010) 116:3865–74. doi: 10.1182/blood-2010-04-282301
131. Brauning A, Rae M, Zhu G, Fulton E, Admasu TD, Stolzing A, et al. Aging of the immune system: focus on natural killer cells phenotype and functions. Cells. (2022) 11:1017. doi: 10.3390/cells11061017
132. Lutz CT, Moore MB, Bradley S, Shelton BJ, and Lutgendorf SK. Reciprocal age related change in natural killer cell receptors for MHC class I. Mech Ageing Dev. (2005) 126:722–31. doi: 10.1016/j.mad.2005.01.004
133. Tizazu AM, Mengist HM, and Demeke G. Aging, inflammaging and immunosenescence as risk factors of severe COVID-19. Immun Ageing. (2022) 19:53. doi: 10.1186/s12979-022-00309-5
134. Ovadya Y and Krizhanovsky V. Senescent cells: SASPected drivers of age-related pathologies. Biogerontology. (2014) 15:627–42. doi: 10.1007/s10522-014-9529-9
135. Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. (2017) 8:14532. doi: 10.1038/ncomms14532
136. Zhu J, Wu C, and Yang L. Cellular senescence in Alzheimer’s disease: from physiology to pathology. Transl Neurodegener. (2024) 13:55. doi: 10.1186/s40035-024-00447-4
137. Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, and Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. (2021) 14:7. doi: 10.1186/s13045-020-01014-w
138. Myers JA and Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. (2021) 18:85–100. doi: 10.1038/s41571-020-0426-7
139. Tang X, Deng B, Zang A, He X, Zhou Y, Wang D, et al. Characterization of age-related immune features after autologous NK cell infusion: Protocol for an open-label and randomized controlled trial. Front Immunol. (2022) 13:940577. doi: 10.3389/fimmu.2022.940577
140. Chelyapov N, Nguyen TT, and Gonzalez R. Autologous NK cells propagated and activated ex vivo decrease senescence markers in human PBMCs. Biochem Biophys Rep. (2022) 32:101380. doi: 10.1016/j.bbrep.2022.101380
141. Bai Z, Yang P, Yu F, Li Z, Yao Z, Martinez J, et al. Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice. Cell Death Dis. (2022) 13:305. doi: 10.1038/s41419-022-04562-w
142. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. (2011) 479:547–51. doi: 10.1038/nature10599
143. Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, et al. Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors. Regener Ther. (2022) 21:185–91. doi: 10.1016/j.reth.2022.07.001
144. Nakazawa T, Maeoka R, Morimoto T, Matsuda R, Nakamura M, Nishimura F, et al. An efficient feeder-free and chemically-defined expansion strategy for highly purified natural killer cells derived from human cord blood. Regener Ther. (2023) 24:32–42. doi: 10.1016/j.reth.2023.05.006
145. Kubo N, Baba M, Shin C, Kasahara Y, Hosokai R, Murayama Y, et al. A novel method for generating chimeric antigen receptor-transduced primary human natural killer cells by the use of multiple cytokines and anti-CD2 and anti-NKp46 stimulatory antibodies. BioMed Pharmacother. (2025) 191:118505. doi: 10.1016/j.biopha.2025.118505
146. Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. (2015) 14:644–58. doi: 10.1111/acel.12344
147. Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. (2019) 40:554–63. doi: 10.1016/j.ebiom.2018.12.052
148. Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. (2018) 36:18–28. doi: 10.1016/j.ebiom.2018.09.015
149. Tavenier J, Nehlin JO, Houlind MB, Rasmussen LJ, Tchkonia T, Kirkland JL, et al. Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mech Ageing Dev. (2024) 222:111995. doi: 10.1016/j.mad.2024.111995
150. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. (2016) 22:78–83. doi: 10.1038/nm.4010
151. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. (2011) 29:909–16. doi: 10.1200/JCO.2010.31.6208
152. Xia W, Chen H, Yang H, Zhu L, Xie C, and Hou M. Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin-related cardiotoxicity. FEBS J. (2024) 291:4029–42. doi: 10.1111/febs.17164
153. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. (2016) 15:428–35. doi: 10.1111/acel.12445
154. Triana-Martinez F, Picallos-Rabina P, Da Silva-Alvarez S, Pietrocola F, Llanos S, Rodilla V, et al. Identification and characterization of Cardiac Glycosides as senolytic compounds. Nat Commun. (2019) 10:4731. doi: 10.1038/s41467-019-12888-x
155. Guerrero A, Herranz N, Sun B, Wagner V, Gallage S, Guiho R, et al. Cardiac glycosides are broad-spectrum senolytics. Nat Metab. (2019) 1:1074–88. doi: 10.1038/s42255-019-0122-z
156. Lee H, Wilson D, Bunting KV, Kotecha D, and Jackson T. Repurposing digoxin for geroprotection in patients with frailty and multimorbidity. Ageing Res Rev. (2023) 86:101860. doi: 10.1016/j.arr.2023.101860
157. Yesilyurt-Dirican ZE, Qi C, Wang YC, Simm A, Deelen L, Hafiz Abbas Gasim A, et al. SGLT2 inhibitors as a novel senotherapeutic approach. NPJ Aging. (2025) 11:35. doi: 10.1038/s41514-025-00227-y
158. Poblocka M, Bassey AL, Smith VM, Falcicchio M, Manso AS, Althubiti M, et al. Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Sci Rep. (2021) 11:20358. doi: 10.1038/s41598-021-99852-2
159. Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. (2020) 583:127–32. doi: 10.1038/s41586-020-2403-9
160. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, et al. Rapamycin slows aging in mice. Aging Cell. (2012) 11:675–82. doi: 10.1111/j.1474-9726.2012.00832.x
161. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. (2009) 460:392–5. doi: 10.1038/nature08221
162. Xu M, Tchkonia T, Ding H, Ogrodnik M, Lubbers ER, Pirtskhalava T, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U.S.A. (2015) 112:E6301–10. doi: 10.1073/pnas.1515386112
163. Moiseeva O, Deschenes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell. (2013) 12:489–98. doi: 10.1111/acel.12075
164. Belakova B, Wedige NK, Awad EM, Hess S, Oszwald A, Fellner M, et al. Lipophilic statins eliminate senescent endothelial cells by inducing anoikis-related cell death. Cells. (2023) 12:2836. doi: 10.3390/cells12242836
165. Fularski P, Krzeminska J, Lewandowska N, Mlynarska E, Saar M, Wronka M, et al. Statins in chronic kidney disease-effects on atherosclerosis and cellular senescence. Cells. (2023) 12:1679. doi: 10.3390/cells12131679
166. Zhou YF, Wang Y, Wang G, Zhou Z, Chen S, Geng T, et al. Association between statin use and progression of arterial stiffness among adults with high atherosclerotic risk. JAMA Netw Open. (2022) 5:e2218323. doi: 10.1001/jamanetworkopen.2022.18323
167. Weyand CM and Goronzy JJ. Aging of the immune system. Mechanisms and therapeutic targets. Ann Am Thorac Soc. (2016) 13:S422–S8. doi: 10.1513/AnnalsATS.201602-095AW
168. Song P, An J, and Zou MH. Immune clearance of senescent cells to combat ageing and chronic diseases. Cells. (2020) 9:671. doi: 10.3390/cells9030671
169. van Deursen JM. The role of senescent cells in ageing. Nature. (2014) 509:439–46. doi: 10.1038/nature13193
170. d’Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. (2008) 8:512–22. doi: 10.1038/nrc2440
171. Franzen J, Zirkel A, Blake J, Rath B, Benes V, Papantonis A, et al. Senescence-associated DNA methylation is stochastically acquired in subpopulations of mesenchymal stem cells. Aging Cell. (2017) 16:183–91. doi: 10.1111/acel.12544
172. Takahashi A, Okada R, Nagao K, Kawamata Y, Hanyu A, Yoshimoto S, et al. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. Nat Commun. (2017) 8:15287. doi: 10.1038/ncomms15287
173. Amor C, Fernandez-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging. (2024) 4:336–49. doi: 10.1038/s43587-023-00560-5
174. Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. (2014) 20:463–73. doi: 10.1016/j.bbmt.2014.01.006
175. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. (2018) 131:2515–27. doi: 10.1182/blood-2017-12-823757
176. Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, et al. Phase I trial of ALT-803, A novel recombinant IL15 complex, in patients with advanced solid tumors. Clin Cancer Res. (2018) 24:5552–61. doi: 10.1158/1078-0432.CCR-18-0945
Keywords: adoptive immunotherapy, antiaging, immunotherapy, NK cell, senescence
Citation: Nakazawa T, Yamanishi R, Morimoto T and Matusda R (2026) Natural killer cell-based senotherapy: a promising strategy for healthy aging. Front. Immunol. 16:1737572. doi: 10.3389/fimmu.2025.1737572
Received: 02 November 2025; Accepted: 17 December 2025; Revised: 16 December 2025;
Published: 12 January 2026.
Edited by:
Cai Zhang, Shandong University, ChinaReviewed by:
Supreet Khanal, United States Food and Drug Administration, United StatesHiroshi Terunuma, Biotherapy Institute of Japan, Inc., Japan
Copyright © 2026 Nakazawa, Yamanishi, Morimoto and Matusda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tsutomu Nakazawa, bmFrYXphd2FAZ3JhbmRzb3VsLWltbXVuby5jby5qcA==